Posters

Comparison of clinical outcomes after LASIK in 1052 eyes using two lasers: the 60 kHz vs the 150 kHz femtosecond laser

Poster Details

First Author: D.Mathur INDIA

Co Author(s):    N. Shroff   R. Dutta                 

Abstract Details

Purpose:

To compare the safety, efficacy, stability, predictability, corneal higher order aberrations (HOA), flap related complications, contrast sensitivity and overall patient satisfaction after Femtosecond LASIK using the FS60 and iFS 150 Femtosecond Lasers.

Setting:

Cornea and Refractive Services, Shroff Eye Centre,Kailash Colony, New Delhi, India.

Methods:

1052 eyes of 573 patients underwent flap creation either with IntraLase FS60 or the IntraLase IFS 150 Femtosecond Laser (AMO). The pre-operative and intra-operative data was comparable in the two groups. The ablation was performed with the AMO VISX S4 IR Excimer Laser. At 12 months the refraction, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), anterior corneal Higher Order Aberration (HOA) was measured with the Oculus Pentacam HR. Contrast sensitivity and patient satisfaction were recorded pre-operatively and 12 months postoperatively.

Results:

12 months postoperatively there were no significant differences in any parameter studied. The Mean residual spherical equivalent in the FS60 group was -0.046±0.37 D and in the iFS150 group was -0.038±0.26 D. The mean UDVA in the FS60 group was 0.007±0.032 logMAR, and 0.010±0.52 logMAR in the iFS150 group. Mean CDVA in the FS60 group was -0.010±0.047 logMAR and in the iFS150 group was -0.006 ± 0.016 logMAR. There was no difference in corneal HOAs. Contrast sensitivity, and incidence of complications were comparable in both groups at 12 months. Early postoperative patient satisfaction was higher in the iFS150 group.

Conclusions:

Visual and optical outcomes were comparable between both Femtosecond Laser Groups. Both Femtosecond Lasers provide high patient satisfaction. The iFS150 Group showed a higher early post-operative patient satisfaction. At 12 months, both treatments were safe, effective and comparable.

Financial Disclosure:

NONE